U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H9F3N2O2
Molecular Weight 270.2073
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0
Stereo Comments Teriflunomide then can interconvert between the E and Z enolic forms (and the corresponding keto-amide), with the Z-enol being the most stable and therefore most predominant form (https://en.wikipedia.org/wiki/Leflunomide)

SHOW SMILES / InChI
Structure of TERIFLUNOMIDE

SMILES

C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F

InChI

InChIKey=UTNUDOFZCWSZMS-YFHOEESVSA-N
InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-

HIDE SMILES / InChI

Molecular Formula C12H9F3N2O2
Molecular Weight 270.2073
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9666414

Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries. Leflunomide is an isoxazole immunomodulatory agent that inhibits dihydroorotate dehydrogenase (a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Several in vivo and in vitro experimental models have demonstrated an anti-inflammatory effect. Leflunomide is rapidly metabolized to its active form, teriflunomide (A77 1726). Two mechanisms of action have been identified for A77 1726: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases. DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action. Human dihydroorotate dehydrogenase consists of 2 domains: an α/β-barrel domain containing the active site and an α-helical domain that forms a tunnel leading to the active site. A77 1726 binds to the hydrophobic tunnel at a site near the flavin mononucleotide. Inhibition of dihydroorotate dehydrogenase by A77 1726 prevents production of rUMP by the de novo pathway; such inhibition leads to decreased rUMP levels, decreased DNA and RNA synthesis, inhibition of cell proliferation, and G1 cell cycle arrest. It is through this action that leflunomide inhibits autoimmune T-cell proliferation and production of autoantibodies by B cells. Since salvage pathways are expected to sustain cells arrested in the G1 phase, the activity of leflunomide is cytostatic rather than cytotoxic. Tyrosine kinases activate signalling pathways leading to DNA repair, apoptosis and cell proliferation. Inhibition of tyrosine kinases can help to treating cancer by preventing repair of tumor cells. Teriflunomide is also an inhibitor of CYP2C8 in vivo. In patients taking leflunomide, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking leflunomide, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking leflunomide.

CNS Activity

Curator's Comment: Teriflunomide, is the active metabolite of leflunomide, has only limited penetration across the blood–brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q02127
Gene ID: 1723.0
Gene Symbol: DHODH
Target Organism: Homo sapiens (Human)
160.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AUBAGIO

Approved Use

Indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Launch Date

1.34740797E12
Palliative
ARAVA

Approved Use

Leflunomide is indicated in adults for the treatment of active rheumatoid arthritis (RA): to reduce signs and symptoms to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing to improve physical function (see CLINICAL STUDIES ). Aspirin, nonsteroidal anti-inflammatory agents and/or low dose corticosteroids may be continued during treatment with leflunomide (see PRECAUTIONS: Drug Interactions: NSAIDs ). The combined use of leflunomide with antimalarials, intramuscular or oral gold, D penicillamine, azathioprine, or methotrexate has not been adequately studied (see WARNINGS: Immunosuppression Potential/Bone Marrow Suppression ).

Launch Date

9.0538561E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.06 μg/mL
7 mg single, oral
dose: 7 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERIFLUNOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
100 μg × h/mL
7 mg single, oral
dose: 7 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERIFLUNOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
243 h
7 mg single, oral
dose: 7 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERIFLUNOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
TERIFLUNOMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.923
unhealthy, 36
n = 250
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 36
Sex: M+F
Population Size: 250
Sources: Page: p.923
Disc. AE: ALT increased, Hepatic enzyme increased...
AEs leading to
discontinuation/dose reduction:
ALT increased (3.6%)
Hepatic enzyme increased (0.4%)
Sources: Page: p.923
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.8,9
unhealthy, 37
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 37
Sex: M+F
Sources: Page: p.8,9
Disc. AE: ALT increased...
AEs leading to
discontinuation/dose reduction:
ALT increased (2.6%)
Sources: Page: p.8,9
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.2781
unhealthy, 37.8 ± 9.7
n = 43
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 37.8 ± 9.7
Sex: M+F
Population Size: 43
Sources: Page: p.2781
Disc. AE: ALT increased, AST increased...
AEs leading to
discontinuation/dose reduction:
ALT increased (4.7%)
AST increased (4.7%)
Neutropenia (4.7%)
Sources: Page: p.2781
672 mg single, oral
Overdose
Dose: 672 mg
Route: oral
Route: single
Dose: 672 mg
Sources:
unknown
Health Status: unknown
Sources:
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
Disc. AE: Hepatotoxicity, Liver injury...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Liver injury (severe)
Liver failure (grade 5)
Disorder fetal
Sources: Page: p.1
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.7
Disc. AE: Peripheral neuropathy...
AEs leading to
discontinuation/dose reduction:
Peripheral neuropathy (1.9%)
Sources: Page: p.7
AEs

AEs

AESignificanceDosePopulation
Hepatic enzyme increased 0.4%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.923
unhealthy, 36
n = 250
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 36
Sex: M+F
Population Size: 250
Sources: Page: p.923
ALT increased 3.6%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.923
unhealthy, 36
n = 250
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 36
Sex: M+F
Population Size: 250
Sources: Page: p.923
ALT increased 2.6%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.8,9
unhealthy, 37
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 37
Sex: M+F
Sources: Page: p.8,9
ALT increased 4.7%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.2781
unhealthy, 37.8 ± 9.7
n = 43
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 37.8 ± 9.7
Sex: M+F
Population Size: 43
Sources: Page: p.2781
AST increased 4.7%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.2781
unhealthy, 37.8 ± 9.7
n = 43
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 37.8 ± 9.7
Sex: M+F
Population Size: 43
Sources: Page: p.2781
Neutropenia 4.7%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.2781
unhealthy, 37.8 ± 9.7
n = 43
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 37.8 ± 9.7
Sex: M+F
Population Size: 43
Sources: Page: p.2781
Disorder fetal Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
Hepatotoxicity Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
Liver failure grade 5
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
Liver injury severe
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
Peripheral neuropathy 1.9%
Disc. AE
14 mg 1 times / day multiple, oral
Recommended
Dose: 14 mg, 1 times / day
Route: oral
Route: multiple
Dose: 14 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.7
PubMed

PubMed

TitleDatePubMed
Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
1998 May 1
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
1999 Feb 15
The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis.
2001
A clinical and economic review of disease-modifying antirheumatic drugs.
2001
A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis.
2001
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.
2001
Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
2001 Apr
The Saccharomyces cerevisiae MLF6/YPL244C gene, which encodes a possible yeast homologue of mammalian UDP-galactose transporter, confers resistance to the immunosuppressive drug, leflunomide.
2001 Aug
[Leflunomide plus methotrexate. Hope for patients with rheumatoid arthritis].
2001 Aug 23
Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
2001 Aug 27
[New basic therapeutic drugs from the viewpoint of evidence-based therapy].
2001 Dec
[Evidence-based medicine and applying new therapies in general practice: wish and reality].
2001 Dec
Progress in the treatment of rheumatoid arthritis.
2001 Dec 12
Leflunomide Aventis Pharma.
2001 Feb
[Leflunomide--the first specific disease-modifying drug against rheumatoid arthritis].
2001 Feb 7
Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro.
2001 Jul 1
Treatment of immune-mediated skin diseases: future perspectives.
2001 Jul-Aug
Treating early rheumatoid arthritis in the younger patient.
2001 Jun
Conventional DMARD options for patients with a suboptimal response to methotrexate.
2001 Jun
Aromatic quinolinecarboxamides as selective, orally active antibody production inhibitors for prevention of acute xenograft rejection.
2001 Jun 7
How is it best to treat early rheumatoid arthritis patients?
2001 Mar
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
2001 May
Comorbidity in rheumatoid arthritis.
2001 May
Inhibition of cyclosporin-resistant B-cell antigen responses by pyrazoles: a tool for the identification of novel molecular mechanisms of B-cell activation.
2001 May
Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
2001 May
Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation.
2001 May
Leflunomide-associated weight loss in rheumatoid arthritis.
2001 May
[Chronic polyarthritis].
2001 May 24
Hamster cardiac xenografts are protected against antibody mediated damage, early after transplantation to Lewis rats.
2001 Nov
Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappaB activation.
2001 Nov-Dec
Severe liver damage with leflunomide.
2001 Oct
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
2001 Oct
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
2001 Oct
Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment.
2001 Oct 15
Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
2001 Sep
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
2001 Sep
[Rheumatic pain].
2001 Sep
Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
2001 Sep
Modulation of inducible nitric oxide synthase activation by immunosuppressive drugs.
2001 Sep
[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
2001 Sep 29
Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl)phenyl]propenamide inhibits IgE/FcepsilonRI receptor-mediated mast cell leukotriene release and allergic asthma in mice.
2001 Sep-Oct
Treating rheumatoid arthritis with new disease modifying drugs.
2002
Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.
2002
Experiences with leflunomide in solid organ transplantation.
2002 Feb 15
[Treatment of cutaneous leishmaniasis--an update].
2002 Jan
Leflunomide induced fevers, thrombocytosis, and leukocytosis in a patient with relapsing polychondritis.
2002 Jan
Effect of hemodialysis on leflunomide plasma concentrations.
2002 Jan
Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference.
2002 Jan
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
2007 Jan 25
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

7 mg or 14 mg orally once daily, with or without food
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:19 UTC 2023
Edited
by admin
on Fri Dec 15 15:43:19 UTC 2023
Record UNII
1C058IKG3B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERIFLUNOMIDE
DASH   INN   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
TERIFLUNOMIDE [MI]
Common Name English
teriflunomide [INN]
Common Name English
AUBAGIO
Brand Name English
HMR-1726
Code English
LEFLUNOMIDE RELATED COMPOUND B
USP  
Common Name English
TERIFLUNOMIDE [USAN]
Common Name English
HMR1726
Code English
LEFLUNOMIDE RELATED COMPOUND B [USP IMPURITY]
Common Name English
2-BUTENAMIDE, 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-, (2Z)-
Systematic Name English
LEFLUNOMIDE IMPURITY B [EP IMPURITY]
Common Name English
TERIFLUNOMIDE [ORANGE BOOK]
Common Name English
A77 1726
Code English
TERIFLUNOMIDE [VANDF]
Common Name English
Teriflunomide [WHO-DD]
Common Name English
TERIFLUNOMIDE [EP MONOGRAPH]
Common Name English
LEFLUNOMIDE RELATED COMPOUND B [USP-RS]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548525
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
WHO-VATC QL04AA31
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
NCI_THESAURUS C471
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
EMA ASSESSMENT REPORTS AUBAGIO (AUTHORIZED: MULTIPLE SCLEROSIS)
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
NDF-RT N0000185502
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
WHO-ATC L04AA31
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
Code System Code Type Description
DRUG BANK
DB08880
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
CHEBI
68540
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
PUBCHEM
54684141
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
EVMPD
SUB25218
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
RS_ITEM_NUM
1357056
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
MESH
C527525
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
WIKIPEDIA
TERIFLUNOMIDE
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
USAN
YY-88
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
FDA UNII
1C058IKG3B
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
LACTMED
Teriflunomide
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
INN
7761
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
SMS_ID
100000089234
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
NDF-RT
N0000185501
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY Dihydroorotate Dehydrogenase Inhibitors [MoA]
MERCK INDEX
m10578
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL973
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
CAS
108605-62-5
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
NCI_THESAURUS
C76662
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
DAILYMED
1C058IKG3B
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
DRUG CENTRAL
4634
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
IUPHAR
6844
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
RXCUI
1310520
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY RxNorm
CAS
163451-81-8
Created by admin on Fri Dec 15 15:43:19 UTC 2023 , Edited by admin on Fri Dec 15 15:43:19 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
EXCRETED UNCHANGED
FECAL
TRANSPORTER -> INHIBITOR
Terifluniomide is an inhibitor of BCRP, OAT3, OATP1B1, OCT2 in vitro
TRANSPORTER -> INHIBITOR
Terifluniomide is an inhibitor of BCRP, OAT3, OATP1B1, OCT2 in vitro
EXCRETED UNCHANGED
URINE
TRANSPORTER -> INHIBITOR
Terifluniomide is an inhibitor of BCRP, OAT3, OATP1B1, OCT2 in vitro
TARGET -> INHIBITOR
INHIBITOR
IC50
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
TRANSPORTER -> INHIBITOR
Terifluniomide is an inhibitor of BCRP, OAT3, OATP1B1, OCT2 in vitro
TRANSPORTER -> SUBSTRATE
Teriflunomide is a substrate of BCRP in vitro
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
4-TFMA was not detected in the single dose metabolism study, but was detected in very small amount after repeated dosing in clinical trials 4-TFMA plasma concentrations were measurable at relatively low concentrations after repeated teriflunomide doses of 7 mg (≤1.7 ng/mL) and 14 mg (≤5.31 ng/mL) for 468 weeks.
MINOR
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC DOSE

Tmax PHARMACOKINETIC ORAL ADMINISTRATION